Ion channels in health and disease. 83rd Boehringer Ingelheim Fonds International Titisee Conference.

Ion channels are key molecules for signal transduction across biological membranes. Combining physiological experiments with DNA sequence data has recently linked many diseases to defects in ion channels and, to acknowledge this, the term ‘channelopathies’ has been coined. While drugs acting on ion channels have long been used as therapeutics, their potential for specific treatment of channelopathies is only now beginning to be elucidated. Plasma membrane ion channels are easy to access and are often expressed at relatively low concentrations in specified cells and tissues, which can make them excellent targets for drug design. While new ion channels are still being characterized, an important dimension has been added to ion channel research: understanding their relevance in pathophysiological processes and ion channel linked diseases. To acknowledge this development, the Boehringer Ingelheim Fonds (http:// www.bifonds.de), an independent foundation for basic research in medicine, has focussed its 83rd International Titisee Conference on ‘Ion channels in health and disease’. About 50 researchers from Europe, USA and Japan met in Titisee, Germany from March 21–25, 2001 to learn from each other how different ion channels are involved in physiological and pathophysiological cell functions. The discussed channel defects and the correlated diseases are summarized and referenced in Table I. In the following report, ion channels are grouped according to their selectivity and their activation mechanism.

[1]  V. Flockerzi,et al.  Expression of CaT-like, a Novel Calcium-selective Channel, Correlates with the Malignancy of Prostate Cancer* , 2001, The Journal of Biological Chemistry.

[2]  A. Schulz,et al.  Loss of the ClC-7 Chloride Channel Leads to Osteopetrosis in Mice and Man , 2001, Cell.

[3]  P. Sieving,et al.  Mutations in the CNGB3 gene encoding the beta-subunit of the cone photoreceptor cGMP-gated channel are responsible for achromatopsia (ACHM3) linked to chromosome 8q21. , 2000, Human molecular genetics.

[4]  G. Ebers,et al.  A novel sodium channel mutation in a family with hypokalemic periodic paralysis , 1999, Neurology.

[5]  L. Pardo,et al.  Oncogenic potential of EAG K+ channels , 1999, The EMBO journal.

[6]  M. Hutchinson,et al.  Mutation of the acetylcholine receptor ε‐subunit promoter in congenital myasthenic syndrome , 1999 .

[7]  Thomas Friedrich,et al.  KCNQ4, a Novel Potassium Channel Expressed in Sensory Outer Hair Cells, Is Mutated in Dominant Deafness , 1999, Cell.

[8]  Samuel F. Berkovic,et al.  Febrile seizures and generalized epilepsy associated with a mutation in the Na+-channel ß1 subunit gene SCN1B , 1998, Nature Genetics.

[9]  S. Jacobson,et al.  Total colourblindness is caused by mutations in the gene encoding the α-subunit of the cone photoreceptor cGMP-gated cation channel , 1998, Nature Genetics.

[10]  Dennis E Bulman,et al.  Familial Hemiplegic Migraine and Episodic Ataxia Type-2 Are Caused by Mutations in the Ca2+ Channel Gene CACNL1A4 , 1996, Cell.

[11]  Bernard C. Rossier,et al.  Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1 , 1996, Nature Genetics.

[12]  J. Inazawa,et al.  Reconstitution of IKATP: An Inward Rectifier Subunit Plus the Sulfonylurea Receptor , 1995, Science.

[13]  I. Scheffer,et al.  A missense mutation in the neuronal nicotinic acetylcholine receptor α4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy , 1995, Nature Genetics.

[14]  K. Ohno,et al.  Mutation of the acetylcholine receptor α subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding affinity , 1995, Neuron.

[15]  J. Bryan,et al.  Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. , 1995, Science.

[16]  E. Hatchwell,et al.  Isolation and partial characterization of a chloride channel gene which is expressed in kidney and is a candidate for Dent's disease (an X-linked hereditary nephrolithiasis). , 1994, Human molecular genetics.

[17]  Michael Litt,et al.  Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1 , 1994, Nature Genetics.

[18]  Andrew G. Engel,et al.  Dihydropyridine receptor mutations cause hypokalemic periodic paralysis , 1994, Cell.

[19]  P. O'Connell,et al.  Mutations in the α1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia , 1993, Nature Genetics.

[20]  M. Phillips,et al.  A mutation in the human ryanodine receptor gene associated with central core disease , 1993, Nature Genetics.

[21]  C. Doriguzzi,et al.  Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia , 1993, Nature Genetics.

[22]  K. Grzeschik,et al.  The skeletal muscle chloride channel in dominant and recessive human myotonia. , 1992, Science.

[23]  M. Leppert,et al.  Mutations in an S4 segment of the adult skeletal muscle sodium channel cause paramyotonia congenita , 1992, Neuron.

[24]  J. Haines,et al.  Hyperkalemic periodic paralysis and the adult muscle sodium channel alpha-subunit gene. , 1990, Science.

[25]  P. Sieving,et al.  Mutations in the CNGB 3 gene encoding the β-subunit of the cone photoreceptor cGMP-gated channel are responsible for achromatopsia ( ACHM 3 ) linked to chromosome 8 q 21 , 2000 .

[26]  Mark Leppert,et al.  A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns , 1998, Nature Genetics.

[27]  Robin J. Leach,et al.  A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family , 1998, Nature Genetics.

[28]  William B. Dobyns,et al.  Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the α1A-voltage-dependent calcium channel , 1997, Nature Genetics.

[29]  G. Ebers,et al.  A novel sodium channel mutation causing Hypokalemic periodic paralysis. , 1997 .